0
0.5
1
1.5+
All studies
-19%
7
16,883
Improvement, Studies, Patients
Relative Risk
Mortality
0%
3
14,930
Ventilation
25%
2
1,831
ICU admission
9%
1
1,831
Hospitalization
-43%
2
91
Cases
-10%
4
14,961
RCTs
-557%
1
91
Peer-reviewed
-45%
6
16,883
Symptomatic
-61%
5
15,821
Prophylaxis
-11%
6
16,792
Late
-557%
1
91
Cannabidiol for COVID-19
c19early.org
March 2024
Favorscannabidiol
Favorscontrol